CuraGen, COR Collaborate In Product Discovery, Pharmacogenomics Deal | GenomeWeb

NEW HAVEN, Conn.--CuraGen recently announced a product discovery and pharmacogenomics agreement with COR Therapeutics. CuraGen said it will apply its SeqCalling, GeneCalling, and PathCalling technologies; related services; and pharmacogenomics expertise to identify new drug targets and develop new cardiovascular drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.